Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI™ enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma.
Antibodies, Viral
/ blood
Betacoronavirus
/ isolation & purification
COVID-19
Clinical Laboratory Techniques
/ methods
Coronavirus Infections
/ blood
Enzyme-Linked Immunosorbent Assay
/ methods
Female
Humans
Immunoassay
/ methods
Male
Pandemics
Pneumonia, Viral
/ blood
SARS-CoV-2
Serologic Tests
/ methods
Antibody testing
COVID-19
ECLIA
SARS-CoV-2
Serological test
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
03
05
2020
revised:
28
05
2020
accepted:
28
05
2020
pubmed:
3
6
2020
medline:
1
9
2020
entrez:
3
6
2020
Statut:
ppublish
Résumé
Here, we report on a head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI SARS-CoV-2 antibodies were measured with the Elecsys® assay and the EDI In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys® assay, of 94% for the EDI Our results indicate a high sensitivity and specificity for the Elecsys® assay and an acceptable agreement with the EDI
Sections du résumé
BACKGROUND
BACKGROUND
Here, we report on a head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI
METHODS
METHODS
SARS-CoV-2 antibodies were measured with the Elecsys® assay and the EDI
RESULTS
RESULTS
In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys® assay, of 94% for the EDI
CONCLUSIONS
CONCLUSIONS
Our results indicate a high sensitivity and specificity for the Elecsys® assay and an acceptable agreement with the EDI
Identifiants
pubmed: 32485155
pii: S0009-8981(20)30261-8
doi: 10.1016/j.cca.2020.05.049
pmc: PMC7261064
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-21Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Clin Chem Lab Med. 2020 Jun 25;58(7):1156-1159
pubmed: 32301750
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088
pubmed: 32301749
Lancet Infect Dis. 2020 Jul;20(7):809-815
pubmed: 32330439
Clin Chem. 2020 Apr 1;66(4):549-555
pubmed: 32031583
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
mBio. 2020 Mar 26;11(2):
pubmed: 32217609